The biopharmaceutical industry is undergoing a transformation, especially in the area of Patient Support Programs (PSPs). Based on a survey of 150 biopharma executives and consultants conducted by CardinoHealth in partnership with BioPharma Dive, we can draw the following three key conclusions that highlight the rapid growth of PSPs in today’s pharmaceutical industry.
One: Helping who is the primary goal
Nearly half of those surveyed believe that determining eligibility for participation in a PSP is one of the most important goals. This shows that pharmaceutical companies are increasingly focused on ensuring that PSPs are actually helping those patients who need them. In the past, PSPs may have simply expanded coverage, but now they are more focused on special cases and individual needs. This means that pharmaceutical companies need to be more precise in identifying which patients could benefit from PSPs to ensure that resources are allocated appropriately. This shift means that the PSP is no longer just a prescription adjunct, but a comprehensive program that cares about the patient’s needs.
2. The criticality of data collection
According to the survey, PSP’s data collection has expanded from being limited to patient-side content to integrating medical-side workflows. This means that pharmaceutical companies have access to a more comprehensive and rich picture of the patient journey, which is essential to provide better support. Automated data collection techniques are also becoming increasingly important to ensure the accuracy and timeliness of information. This will help improve the performance of the PSP and make it more in line with the needs of the patient. Therefore, PSPs need not only to have a wealth of data, but also to use modern technology to ensure that information is used effectively.
3. The importance of relay services
PSP services act as a relay station in the patient journey, providing biopharma companies with valuable inside insights and going beyond the value of just delivering drugs. One of the future trends is to involve more patients in the development of PSP services, which will make PSPs more personalized and relevant to real needs. It also means that biopharma companies need to be more flexible and open to meet patient engagement and contributions. Relay services are not only about providing information, but also about building interaction and trust between patients and pharmaceutical companies.
In summary, the biopharmaceutical industry is actively transforming, and patient support programs (PSPs) are one of the key drivers of this transformation. Ensuring that patients in need are truly helped relies on the determination of eligibility, extensive data collection, and the provision of relay services. This shift will not only affect pharmaceutical companies, but will also have a profound impact on the health and quality of life of the general public. As a result, pharmaceutical companies need more innovative and individualized approaches to ensure that PSPs best meet patient needs, which in turn improves treatment outcomes, improves quality of life, and is more focused on patient needs and expectations. This transformation is both a challenge and an opportunity to care more about and support our health.
Evie Wang, Director of Lighting Strategy Consultants
[email protected]
